BofA analyst Joanna Gajuk raised the firm’s price target on Tenet Healthcare (THC) to $225 from $205 and keeps a Buy rating on the shares. While hospital fundamentals should remain solid in the second half, the firm is concerned that the policy and reimbursement environment will be more negative compared to recent years, says the analyst, who prefers post-acute over hospitals as the least exposed to the upcoming cuts given this backdrop. The firm is updating estimates and price targets for several companies in its health care facilities coverage.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare’s Strategic Positioning and Growth Potential Justify Buy Rating
- 3 “Strong Buy” Value Stocks to Buy Now, 8/6/2025, According to Analysts
- Tenet Healthcare downgraded to Peer Perform from Outperform at Wolfe Research
- Tenet Healthcare price target lowered to $167 from $195 at Baird
- Tenet Healthcare’s Strong Financial Performance and Strategic Initiatives Drive Buy Rating